Single Agent Abraxane as Second Line Therapy in Bladder Cancer

Status Completed

Clinical Trial Summary

The purpose of this study is to determine what effects the drug Abraxane has on bladder cancer.

Clinical Trial Description

For those patients with advanced bladder cancer who have progressed on a platinum based regimen, no widely accepted standard second line therapy currently exists. Taxanes including paclitaxel have exhibited clinical activity in this disease and are sometimes given off study. However, toxicities including neurotoxicity and hypersensitivity reactions often limit the use of paclitaxel. ABRAXANE may allow delivery of a greater dose of paclitaxel to those with bladder cancer with an easier method of administration and with less toxicity. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00683059
Study type	Interventional
Source	Sunnybrook Health Sciences Centre
Contact
Status	Completed
Phase	Phase 2
Start date	March 2008
Completion date	June 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03296306` - Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma	Phase 3
Completed	`NCT00880334` - Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC	Phase 2
Completed	`NCT00216801` - Relationship of Ochratoxin A to Upper Urologic Cancers	N/A
Withdrawn	`NCT04179110` - Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor	Phase 2
Completed	`NCT00070070` - Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas	Phase 1
Completed	`NCT00154687` - Weekly TP-HDFL in the Treatment of Advanced TCC	Phase 2
Completed	`NCT03256877` - Detecting Transitional Cell Carcinoma From Haematuria
Withdrawn	`NCT04006691` - Efficacy and Safety of UGN-101 in Recurrent Patients	Phase 3
Terminated	`NCT05052372` - Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
Completed	`NCT00714025` - A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy	Phase 2
Terminated	`NCT01310803` - Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder	Phase 3
Completed	`NCT00623831` - A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen	Phase 1
Completed	`NCT00173862` - Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC	Phase 2
Recruiting	`NCT03896958` - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Terminated	`NCT01438112` - Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer	Phase 2/Phase 3
Recruiting	`NCT04811846` - CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood	N/A
Not yet recruiting	`NCT04878250` - Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder	Phase 2
Completed	`NCT00633789` - Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types	Phase 2
Completed	`NCT00612326` - Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging	N/A
Active, not recruiting	`NCT03219775` - Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma	Phase 2